Forbion Raises $2.3B Led by Eli Lilly

Forbion raises $2.3B Series A+ led by Eli Lilly.

Other participants in this funding round include PGGM, MN, KfW Capital, and the Kauffman Foundation. Forbion develops novel therapies and is focused on backing approximately 30 biopharma companies. The company is led by CEO Sander Slootweg.

With this significant capital, Forbion aims to address the growing need for investment in the biotech sector, which is facing a shortage of funding. Their recent fundraising effort is expected to bolster assets under management to around $7.5B, enhancing their ability to invest in promising biopharma innovations.

Historically, Forbion has maintained a strong track record in the venture capital space, consistently financing companies that have successfully delivered approved medical products, impacting a vast number of patients worldwide. This latest funding move reaffirms their commitment to supporting transformative healthcare solutions.

Company	Forbion
Amount	$2.3B
Lead Investor	Eli Lilly
Investors	PGGM, MN, KfW Capital, Kauffman Foundation
Founders	Sander Slootweg (Co-founder, Managing Partner), Robbert van de Griendt
Sectors	Life Sciences Venture Capital